Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice

Scott Houghtaling, Laura Granville, Yassmine Akkari, Yumi Torimaru, Susan Olson, Milton Finegold, Markus Grompe

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure and an increased susceptibility to cancer. FA is genetically heterogeneous, consisting of at least 11 complementation groups, FA-A through L, including FA-D1 (BBCA2) and D2. We have previously reported an increased incidence of epithelial tumors in Fancd2 knockout mice. To further investigate the role of the FA pathway in tumor prevention, Fancd2 mutant mice were crossed to mice with a null mutation in the tumor suppressor gene, Trp53. The tumor spectrum in Fancd2-/-/Trp53+/- mice included sarcomas expected in Trp53 heterozygotes, as well as mammary and lung adenocarcinomas that occur rarely in Trp53 heterozygotes. These tumors occurred earlier than in Fancd2-/- control mice. Therefore, the Fancd2 -/-/Trp53+/- mice represent an improved model for the study of adenocarcinoma in FA. In addition, it was found that Fancd2 -/- mouse embryonic fibroblasts but not Fancd2-/-/ Trp53-/- mouse embryonic fibroblasts arrest following DNA damage. Therefore, Trp53 is required for the S phase checkpoint activation observed in Fancd2 mutant cells. Fancd2-/-/Trp53-/- cells showed an increase in aneuploidy and had multiple gross chromosomal rearrangements.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalCancer Research
Volume65
Issue number1
StatePublished - Jan 1 2005

Fingerprint

Fanconi Anemia
Knockout Mice
Neoplasms
Heterozygote
Fibroblasts
S Phase Cell Cycle Checkpoints
Aneuploidy
Tumor Suppressor Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. / Houghtaling, Scott; Granville, Laura; Akkari, Yassmine; Torimaru, Yumi; Olson, Susan; Finegold, Milton; Grompe, Markus.

In: Cancer Research, Vol. 65, No. 1, 01.01.2005, p. 85-91.

Research output: Contribution to journalArticle

Houghtaling, Scott ; Granville, Laura ; Akkari, Yassmine ; Torimaru, Yumi ; Olson, Susan ; Finegold, Milton ; Grompe, Markus. / Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. In: Cancer Research. 2005 ; Vol. 65, No. 1. pp. 85-91.
@article{356529149a084ffeb47a73b39d6ddd62,
title = "Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice",
abstract = "Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure and an increased susceptibility to cancer. FA is genetically heterogeneous, consisting of at least 11 complementation groups, FA-A through L, including FA-D1 (BBCA2) and D2. We have previously reported an increased incidence of epithelial tumors in Fancd2 knockout mice. To further investigate the role of the FA pathway in tumor prevention, Fancd2 mutant mice were crossed to mice with a null mutation in the tumor suppressor gene, Trp53. The tumor spectrum in Fancd2-/-/Trp53+/- mice included sarcomas expected in Trp53 heterozygotes, as well as mammary and lung adenocarcinomas that occur rarely in Trp53 heterozygotes. These tumors occurred earlier than in Fancd2-/- control mice. Therefore, the Fancd2 -/-/Trp53+/- mice represent an improved model for the study of adenocarcinoma in FA. In addition, it was found that Fancd2 -/- mouse embryonic fibroblasts but not Fancd2-/-/ Trp53-/- mouse embryonic fibroblasts arrest following DNA damage. Therefore, Trp53 is required for the S phase checkpoint activation observed in Fancd2 mutant cells. Fancd2-/-/Trp53-/- cells showed an increase in aneuploidy and had multiple gross chromosomal rearrangements.",
author = "Scott Houghtaling and Laura Granville and Yassmine Akkari and Yumi Torimaru and Susan Olson and Milton Finegold and Markus Grompe",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "65",
pages = "85--91",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice

AU - Houghtaling, Scott

AU - Granville, Laura

AU - Akkari, Yassmine

AU - Torimaru, Yumi

AU - Olson, Susan

AU - Finegold, Milton

AU - Grompe, Markus

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure and an increased susceptibility to cancer. FA is genetically heterogeneous, consisting of at least 11 complementation groups, FA-A through L, including FA-D1 (BBCA2) and D2. We have previously reported an increased incidence of epithelial tumors in Fancd2 knockout mice. To further investigate the role of the FA pathway in tumor prevention, Fancd2 mutant mice were crossed to mice with a null mutation in the tumor suppressor gene, Trp53. The tumor spectrum in Fancd2-/-/Trp53+/- mice included sarcomas expected in Trp53 heterozygotes, as well as mammary and lung adenocarcinomas that occur rarely in Trp53 heterozygotes. These tumors occurred earlier than in Fancd2-/- control mice. Therefore, the Fancd2 -/-/Trp53+/- mice represent an improved model for the study of adenocarcinoma in FA. In addition, it was found that Fancd2 -/- mouse embryonic fibroblasts but not Fancd2-/-/ Trp53-/- mouse embryonic fibroblasts arrest following DNA damage. Therefore, Trp53 is required for the S phase checkpoint activation observed in Fancd2 mutant cells. Fancd2-/-/Trp53-/- cells showed an increase in aneuploidy and had multiple gross chromosomal rearrangements.

AB - Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure and an increased susceptibility to cancer. FA is genetically heterogeneous, consisting of at least 11 complementation groups, FA-A through L, including FA-D1 (BBCA2) and D2. We have previously reported an increased incidence of epithelial tumors in Fancd2 knockout mice. To further investigate the role of the FA pathway in tumor prevention, Fancd2 mutant mice were crossed to mice with a null mutation in the tumor suppressor gene, Trp53. The tumor spectrum in Fancd2-/-/Trp53+/- mice included sarcomas expected in Trp53 heterozygotes, as well as mammary and lung adenocarcinomas that occur rarely in Trp53 heterozygotes. These tumors occurred earlier than in Fancd2-/- control mice. Therefore, the Fancd2 -/-/Trp53+/- mice represent an improved model for the study of adenocarcinoma in FA. In addition, it was found that Fancd2 -/- mouse embryonic fibroblasts but not Fancd2-/-/ Trp53-/- mouse embryonic fibroblasts arrest following DNA damage. Therefore, Trp53 is required for the S phase checkpoint activation observed in Fancd2 mutant cells. Fancd2-/-/Trp53-/- cells showed an increase in aneuploidy and had multiple gross chromosomal rearrangements.

UR - http://www.scopus.com/inward/record.url?scp=11244341619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244341619&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 85

EP - 91

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -